In patient 2 treatment with l-serine led to an improvement of spasticity.
2
A treatment with oral l-serine was started at age 4.5 years and 3 months respectively.
3
A previous study revealed a novel and unexpected interaction between the hydroxyl group of the l-serine substrate and the 5'-phosphate group of PLP.
4
L-serine or L-cysteine incubation increased NO and S1P levels in mouse aorta.
5
Here, we have investigated if L-serine contributes to the vasorelaxant effect.
6
Key results: L-serine relaxed aorta rings in an endothelium-dependent manner.
7
The enzyme also catalyzes the dehydration of D- and L-serine.
8
We conclude that 3-PGDH can be treated effectively by a combination of L-serine and glycine.
9
Serine racemase (SR) is the enzyme that converts L-serine to D-serine.
10
The L-serine effect involves both NO and S1P.
11
L-serine supplementation also improved measures of motor and sensory performance as well as measures of male fertility.
12
The mutant forms of the enzyme show a shift from their canonical substrate L-serine to the alternative substrate L-alanine.
13
Computer graphics models of the wild-type enzyme complexed with L-serine and D-serine provided an insight into the catalytic mechanisms of both reactions.
14
L-serine supplementation is a possible candidate therapy but the lack of responsive outcome measures is a barrier for undertaking clinical trials in HSN1.
15
One mutant exhibits greatly reduced chemotaxis toward L-serine but has no detectable defect either in uptake or in oxidative metabolism of that compound.
16
Second, various serine analogues were also examined; the data indicated that the alpha-carboxyl group of L-serine was quite important for substrate recognition by SPT.